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Abstract
Introduction. Struma ovarii (SO) is a monodermal teratoma in which thyroid tissue comprises more than 50% 
of the tumour. Papillary thyroid cancer (PTC) in SO is a rare finding, as only 5% of SO cases undergo malignant 
transformation. Malignant SO is usually asymptomatic and infrequently diagnosed preoperatively. Because of 
its rarity, there is no consensus about diagnosis and management, while treatment and follow-up procedures 
are not clearly established.
Material and methods. Herewith, we report two cases of PTC in SO. The first patient was a 25-year-old woman 
diagnosed with bilateral ovarian tumours. The second patient, 19-year-old woman, presented with unilateral 
ovarian mass. Both patients were qualified for surgical excision of the tumours. Histopathological specimens 
underwent both conventional histopathological assessment and immunohistochemical staining. 
Results. In the first patient histopathology revealed SO with two foci of PTC. Immunohistochemically a positive 
expression of CK7, CK19, p63 and thyroglobulin (Tg) confirmed the diagnosis. She underwent total thyroidectomy 
in 2016 in order to enable ablative radioiodine therapy and facilitate further thyroglobulin monitoring. Unfor-
tunately, the patient was lost from follow-up. In the second patient, histopathological diagnosis was follicular 
variant of PTC in SO. Postoperatively, a pelvic CT revealed osteolytic lesion 6 cm in size, being a metastatic 
change. The patient underwent unilateral ovariectomy, total thyroidectomy and multiple cycles of radioiodine 
therapy. Currently, 9 years following the diagnosis, the patient achieved disease remission.
Conclusions. PTC in SO still remains a diagnostic and therapeutic challenge. Immunostaining for CK7, CK19, 
p63 and Tg might be helpful in histopathological diagnosis. The decision on the need of total thyroidectomy and 
radioiodine therapy should be made individually. However, thyroid remnant ablation increases the sensitivity 
and specificity of follow-up testing using serum Tg level as a tumour marker. (Folia Histochemica et Cytobiologica 
2019, Vol. 57, No. 1, 35–41)
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Introduction
Germ cell tumours are a heterogeneous group of 
neoplasms arising from primordial germ cells. The 
most common type of germ cell tumours are terato-
mas [1]. Struma ovarii (SO) is a monodermal germ 
cell tumour characterized by the presence of thyroid 
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tissue in more than 50% [2]. It was first described in 
1899 by Boettlin, who observed the presence of thy-
roid follicular tissue in the ovaries [3]. It is most often 
diagnosed postoperatively during histopathological 
examination, while radiological imaging is unspecific 
[4]. Strumae ovarii are one of the rarest ovarian tu-
mours — they represent 1% of them and comprise 
2–5% of teratomas [5]. Less than 200 cases have been 
so far reported in medical literature [2]. Struma ovarii 
is usually a benign tumour, being histologically and 
pathologically identical to normal thyroid tissue found 
in typical localization. Less than 5% of these tumours 
undergo malignant transformation [2, 6–8]. The age at 
presentation of SO is usually between 40 and 60 years 
[3, 9, 10]. The most common type of cancer within SO 
is well-differentiated thyroid cancer, most commonly, 
papillary thyroid cancer (PTC) [9, 11]. The diagnosis 
of thyroid cancer arising in SO should be based on the 
similar criteria as for primary thyroid gland disease.
Due to the rarity of this type of tumour, there 
has been a paucity of data in the medical literature 
about its optimal diagnosis, treatment and follow-up. 
Classically, the treatment is the surgical resection of 
the ovarian mass. Iodine-131 therapy can be proposed 
after total thyroidectomy, but no consensus exists in 
terms of surveillance and adjuvant treatment [12]. 
Diagnostic difficulties may appear also at the level 
of histopathological examination. In this report we 
present two patients diagnosed postsurgically with 
thyroid cancer in SO and demonstrate the pivotal 
role of immunohistochemical (IHC) staining for final 
diagnosis. 
Material and methods
Herewith we report two cases of PTC in SO. The first patient 
was a 25-year-old woman diagnosed with bilateral ovarian 
tumours. She was suffering from recurrent acute lower 
abdominal pain. Similar episodes of pain were experienced 
during sexual intercourses in the previous two years, since 
she gave birth to a first child via caesarean section. There 
were no other associated gastrointestinal or genitourinary 
symptoms. She was otherwise healthy with nonsignificant 
past medical history. The second patient, 19-year-old 
woman, presented with unilateral ovarian mass. Both pa-
tients underwent clinical assessment, imaging studies and 
were qualified for surgical excision of the ovarian tumours. 
Histopathological specimens underwent both conventional 
histopathological assessment and IHC staining.
Immunohistochemistry. Formalin fixed, paraffin embed-
ded tissue specimens were cut into 4 μm sections. The 
sections were mounted on adhesion microscope slides 
(Dako, Glostrup, Denmark). Deparaffinization, rehydra-
tion and antigen retrieval was achieved by incubation in 
a water bath (PT Link, Dako) in a buffer (High pH, EnVi-
sion FLEX Target Retrieval Solution, Dako) at 97oC for 
20 min. The sections were then machine stained with the 
use of Autostaner Link 48 using a visualization kit for IHC 
staining (EnVision FLEX+, Mouse, Dako). Prediluted pri-
mary antibodies included: mouse monoclonal anti-Human 
Cytokeratin 7 (clone: OV-TL 12/30), monoclonal mouse 
anti-human cytokeratin 19 (clone RCK108, Dako), mono-
clonal mouse anti-human p63 protein (clone: DAK-p63), 
polyclonal rabbit anti-human thyroglobulin (Dako), and 
Rabbit Linker (Dako) for amplification. Then, the slides 
were dehydrated and mounted with cover glass with Mount-
ing Medium (Dako).
Results
In the first patient, an ultrasound examination revealed 
normal sized and shaped uterus and endometrial 
thickness of 4 mm. Moreover, left ovarian cyst 4.7 cm 
in size with dense content and 8.7 cm mass behind 
the uterus suggestive of a teratoma of a right ovary, 
were revealed. Ultrasound pattern was compatible 
with presumably benign tumours; hence, there was 
no need to conduct computed tomography (CT) scans 
or magnetic resonance imaging (MRI). The patient 
was qualified for surgery; due to the size and bilateral 
location of the lesions, the patient was qualified for 
conventional laparotomy. During surgical procedure, 
abdominal cavity and uterus were normal, while the 
ovaries were enlarged and presented bilateral masses 
which were enucleated and removed. Intraoperative 
histopathological examination revealed a teratoma 
on the right side (9.0 × 6.0 × 5.0 cm) with SO and 
dermoid cyst in the left ovary (8.0 × 7.8 × 2.0 cm). 
In the right ovary mass the biggest cyst was 3 cm in 
size and was filled with clear serous fluid. In the oth-
er cysts there was yellow, viscous material. Patient’s 
postoperative period was uneventful.
Microscopic examination of the surgical specimen 
prepared by haematoxylin and eosin (H&E) staining 
(Figs. 1A, B) revealed two foci of PTC in SO (the 
largest 4 mm in size). The diagnosis was confirmed 
by an IHC examination. Immunohistochemically, 
tumour cells were strongly positive for thyroglobulin 
(Tg), cytokeratin 19 (CK19), cytokeratin 7 (CK7) 
and p63 (Figs. 2A–D). Based on all these findings, 
the diagnosis was papillary thyroid cancer arising 
within SO. Subsequently, in order to enable potential 
ablative radioiodine therapy and facilitate further Tg 
monitoring, the patient was referred for total thyroid-
ectomy. The patient had two mixed solid/cystic focal 
lesions in the thyroid (size 8 mm and 11 mm) detected 
on thyroid ultrasound examination. Both presented 
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Figure 1. Microscopic view of papillary thyroid cancer in struma ovarii of the Patient 1. H&E staining. Total magnification 
A. 40× and B. 400×.
A B
C D
Figure 2A. Immunohistochemical (IHC) detection of the studied antigens in the tissue of papillary thyroid cancer in struma 
ovarii of the Patient 1. A. CK19 positive immunoreactivity in the tumor tissue, while negative in the surrounding non-can-
cerous thyroid tissue. B. Immunoreactivity of thyroglobulin. C. Immunoreactivity of cytokeratin 7. D. Immunoreactivity of 
p63. Immunohistoch-emical stainings were performed as described in Methods. Total magnification 400×.
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no sonographic features of malignancy and were 
diagnosed as benign colloid nodules on cytological 
examination of the specimen obtained on fine-needle 
aspiration biopsy. On postsurgical histopathological 
examination there were no malignant lesions found 
in the thyroid, and colloid goitre was diagnosed. After 
surgery the patient was treated with oral L-thyroxine 
therapy and the post-surgical serum Tg concentration 
on suppressive doses measured 6 week following sur-
gery was 0.9 ng/ml, marking the low risk of persistent 
disease. The patient was scheduled for whole-body 
scintiscan and stimulated Tg assessment 3–6 months 
following surgery in order to decide whether to 
administer radioiodine therapy. Unfortunately, the 
patient was lost from follow-up. Still, in this patient 
a long-term regular follow up is required in order 
to monitor Tg concentration and including regular 
gynaecological visits.
The second patient had an unilateral ovarian 
mixed solid and cystic mass (4.0 × 3.0 × 6.8 cm) 
diagnosed during routine gynaecological follow-up. 
An excision of the lesion was performed from lapa-
roscopic approach. Histopathological diagnosis was 
teratoma of the size 6 × 7 × 4 cm that contained focus 
of follicular variant of PTC in SO (size not reported, 
histopathological material unavailable). Two months 
after the surgery, laparoscopic complete right ova-
riectomy was performed and two months later total 
thyroidectomy was performed. No focal lesions were 
detected in the thyroid preoperatively on ultrasound 
examination or postoperatively on histopatholog-
ical examination. Radioiodine therapy was then 
introduced — 200 mCi 131-I was administered. Few 
months later pelvic CT scan revealed an osteolytic 
lesion in the left ilium measuring 4.8 × 5.8 × 1.0 cm, 
being a metastatic change. Whole-body scintiscan 
depicted radioiodine uptake in the metastasis. During 
9 years of follow-up the patient was on constant L-thy-
roxine suppressive therapy and received cumulative 
activity at the level of 1400 mCi of radioiodine. At 
the moment she achieved complete biochemical and 
structural disease remission.
Discussion and conclusions
Most patients with SO present no clinical symptoms 
and are diagnosed incidentally. In some patients, as 
it was in the two presented cases, they may cause 
symptoms similar to those typical of other ovarian 
tumours, such as low abdominal pain, nausea, vag-
inal bleeding and abnormal menstrual cycles [5, 6]. 
Sometimes, the first symptom is palpable abdominal 
mass [5, 7, 13]. The late manifestation of malignant 
SO are signs of metastatic disease such as back pain 
[14, 15]. Dissimilar from previous reports, in two of 
our patients SO was diagnosed in their 19th and 25th 
years of age (in comparison to average 40–60 years 
reported in the literature). The most common type 
of cancer detected in this type of teratoma is PTC, 
as it was in our patients. In one of them follicular 
variant of PTC was diagnosed at the stage of distant 
bone metastasis. Distant metastases from malignant 
SO are highly uncommon and occur in only about 
5% of cases [16]. Tumours can metastasize via direct 
spread to the omentum, peritoneal cavity and con-
tralateral ovary, via the lymphatic system to pelvic and 
para-aortic lymph nodes and via blood to the bones, 
brain, lung, contralateral ovary and liver [16]. Bone 
is a very rare site for metastasis and there are only 
a few cases in the English language literature which 
have reported metastasis to the bones [17–19]. The 
metastatic pattern of malignant SO resembles that 
of ovarian cancer; therefore, for advanced disease 
certain authors propose performing complete staging 
surgery as for ovarian cancer.
Similarly to both our patients, over 92% of the 
patients with thyroid cancer in SO are clinically and 
biochemically euthyroid [3, 20, 21]. However, 83% of 
patients who present with hyperthyroidism already 
had distant metastases from malignant SO [22]. There 
is no typical ultrasound feature of SO, although it 
could be suspected if there is a large solid mass on 
ultrasound examination, as it was in both our patients. 
Tumour markers are not useful and they represent 
low clinical value in these cases. The symptoms are 
also non-specific; therefore, most cases of malignant 
SO have subclinical course and are diagnosed inci-
dentally. Most frequently the patients present with 
pelvic pain. Postsurgical assessment of thyroglobulin 
can be used for follow-up as a marker of response to 
treatment, especially in cases of metastases. 
Both papillary and follicular thyroid cancers aris-
ing in SO have been reported in medical literature 
[16]. The most common type of malignant SO is PTC 
[15, 23, 24]. The pathological diagnosis of malignant 
SO is primarily established according to the criteria 
for tumours of the thyroid gland. These criteria in-
clude ground glass overlapping nuclei and nuclear 
grooves, or mitotic activity and vascular invasion 
[8, 15]. The diagnosis of thyroid cancer in SO might 
be challenging. The “gold standard” in diagnosis 
of thyroid cancers is using routine H&E staining. 
Immunohistochemistry is an additional procedure, 
often necessary to provide diagnosis. Besides H&E 
staining for evaluating thyroid tumour morphology, 
immunohistochemical methods have been widely 
used [25]. Immunohistochemical markers are of two 
types: those related to proteins present in normal 
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thyrocytes (such as thyroglobulin and thyroid tran-
scription factor-1) and those related to proteins in 
pathological thyrocytes (such as CK 19 and Hector 
Battifora mesothelial epitope-1) [26, 27]. 
Cytokeratins (CK), mainly expressed in epithelial 
cells and skin appendages, constitute the largest sub-
group of intermediate filament proteins [28]. They 
participate in the formation of the cell skeleton and 
play an important role in the responses to stress, 
mitosis, the postmitotic period, cell signalling and 
movement, as well as in differentiation and apoptosis 
[26, 29]. CK19 is mainly expressed in ductal epithelium 
(bile and pancreatic ducts, renal collecting ducts) and 
gastrointestinal epithelium [30]. Expression of CK19 
might also be positive in pancreatic neuroendocrine 
tumours, hepatocellular cancer, cervical squamous 
cell cancer, thymic and lung cancers [31–34]. Malig-
nant thyroid lesions present higher CK19 expression 
when compared to nonmalignant thyroid lesions [27]. 
In our patient, we confirmed that CK19 expression in 
the patient’s tumour was positive suggestive of malig-
nant process. Another marker demonstrating positive 
staining in our specimen was CK7. In the study by 
Bejarano et al., 79% of benign and malignant thyroid 
tumours were found to demonstrate positive reaction 
for CK7, especially all eight analysed PTCs [35].
There are only a few studies on the involvement 
of p63 protein in processes associated with thyroid 
tumour formation and they represent contradictory 
results. This protein is a member of p53 family of 
transcription factors having a major role in regu-
lating proliferation and differentiation processes of 
epithelial cells [36]. Immunohistochemical expression 
of p63 is evident in some types of cancers including 
squamous cell cancer, choriocarcinoma and thyroid 
cancer [37–39], and was also demonstrated in our 
patient with PTC.
The optimal treatment guidelines for PTC arising 
in malignant SO are still disputable. Most authors 
advocate for aggressive treatment based on total ab-
dominal hysterectomy with bilateral salpingo-oopho-
rectomy, omentectomy and lymph node dissection [2, 
6, 8, 24]. Because of permanent infertility associated 
with this procedure, unilateral salpingo-oophorec-
tomy/unilateral oophorectomy in order to preserve 
the patients’ fertility is acceptable [2, 40]. As one of 
our patients was nulliparous and the second patient 
had one child, in both gynaecologic intervention was 
limited to an ovarian mass excision to preserve fer-
tility and ovarian hormonal function. It is necessary 
to check the contralateral ovary in order to exclude 
any pathological changes. Moreover, the decision 
on completion thyroidectomy raises controversies. 
Debate remains about the role of total thyroidectomy 
and subsequent radioiodine ablation. Most authors 
suggest aggressive treatment with radioactive iodine 
therapy regardless of the presence or absence of me-
tastases at time of diagnosis [2, 41, 42]. Some authors 
agree that thyroidectomy and radioactive iodine ther-
apy should be undertaken only in case of recurrent 
disease or metastases [43]. In general, completion 
thyroidectomy and radioiodine ablation therapy ap-
pear to be well-accepted and effective treatments for 
malignant SO most often reported in the literature 
[16, 44], which also adheres to the standards applied 
to manage our patients. 
Thyroid-type cancers arising in SO, especially 
the newly recognized entity, i.e. highly differentiated 
follicular cancer of ovarian origin, have a favourable 
prognosis with 5- and 25-year survival rate of 92% 
and 79%, respectively [8, 43, 45]. Long-term follow-up 
with thyroglobulin and anti-thyroglobulin antibodies 
levels assessment is necessary due to the possibility of 
recurrence. Based on the rarity of these tumours and 
lack of firm prognostic factors, therapeutic decisions 
should be made individually, based on pathologic and 
clinical parameters, respecting the patient’s informed 
consent.
In conclusion, PTC in SO still remains a diag-
nostic and therapeutic challenge. The diagnosis is 
most often made postoperatively. Immunostaining 
for CK7, CK19, p63 and thyroglobulin might be 
helpful in histopathological assessment. There is still 
no established treatment algorithm for SO patients. 
The decision on the need of total thyroidectomy and 
radioiodine therapy should be made individually. 
However, thyroid remnant ablation increases the 
sensitivity and specificity of follow-up testing using 
serum thyroglobulin levels as a tumour marker.
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